Drugs and Medicine

Copaxone

Question: What is the difference between the MS drugs Avonex and Copaxone? My son has been taking Avonex for his MS for 3 years now. He has had 3 episodes where he has had to be admitted to the hospital for IV therapy. I noticed that a couple of yahoo members are taking Copaxone and have been on it for 4 years symptom-free. I was wondering if maybe my son should change medications. Another reason for changing is this - after each injection, he gets very ill with a 104 degree fever and flu like symptoms, which last for about 24 hours. We have talked to his doctor about this and he said some people just get sick after their injections. He tried to give him 2 or 3 different medicatoins, hoping they would help with the sick feeling, but none of them worked. Has anyone on the Copaxone ever gotten sick after their injections? I would appreciate everyone who has been on Avonex or Copaxone helping me. My son really needs the help.

Answer: The main difference between Avonex (interferon beta-1a) and Copaxone (glatiramer acetate for injection) is that Avonex was designed to treat a first MS attack, to slow the accumulation of physical disability and to decrease the clinical worsening in those patients with relapsing forms of MS. Copaxone was designed to reduce the frequency of relapse in those patients with relapsing-remitting MS. The two drugs share many of the same common adverse reactions - nausea, diarrhea, abdominal upset to name three. Fever is a common adverse effect of Avenox and a less common adverse reaction to Copaxone. Consider that. Speak to his doctor about the advisability of changing.

 


Copaxone Related Products and News

Momenta Pharmaceuticals' Management Presents at Bank of America Merrill Lynch ...

Seeking Alpha
We have an ANDA under review for a generic Copaxone and we also have initiated a proof of concept clinical study for a novel product M402 a novel oncology product, which we are initiating a trial for in pancreatic cancer. We use intellectual property ...
 

Proactive Investors USA & Canada

Strong growth at Teva as Yanai era ends
Chicago Tribune
 

Haaretz

Copaxone rival okayed again for market after safety review
Haaretz
 

CombiRx Results In: No Benefit to Combining Avonex and Copaxone

About - News & Issues
By Julie Stachowiak, Ph.D., About.com GuideApril 28, 2012 I've been watching the CombiRx trial since I started taking Copaxone in 2005. It seems logical, doesn't it - if Copaxone works to prevent relapses, and Avonex works to prevent relapses, ...
 

Teva Pharmaceuticals' Disappointing Results

Seeking Alpha
There was some fixation on what is characterized as weak Copaxone sales and softness in European sales. What did the analysts have to complain about? Teva is the world's largest generic drug manufacturer by sales and is expanding into the branded ...
 

Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting ...

MarketWatch (press release)
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced interim data from a prospective, open label survey study evaluating spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to COPAXONE(R) (glatiramer ...
 

Study finds Teva's Copaxone reduces spasticity in MS patients

Globes
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) reports interim data from a study, which suggests that multiple sclerosis patients who switched to Copaxone from interferon-beta treatment showed a significant reduction in spasticity.
 

TEVA's Q1 Effect on Specialty Pharma

Forbes
Teva Pharmaceuticals (TEVA), BUY ? $52 target: We still see a Copaxone win as the key driver and like the risk/reward. A Copaxone win is needed and while the magnitude of upside on a win could be trimmed if EU headwinds persist (which we have to ...
 

Researchers finally publish report on JC virus (video)

Examiner.com
... differently because of the low risk in the subgroup of patients?, which includes people like Pamela Vaughn of Lima: ?I've been on Copaxone for about a year now, I'd changed from Rebif since I'd been having new difficulties with my MS,? she said.
 

This Just In: Upgrades and Downgrades

DailyFinance
And worst-case, Needham thinks there's only 10% to 15% "downside" in the stock at today's prices, "even in the event of a negative outcome in patent litigation against generic Copaxone filers." The real problem, it seems, is Needham's worry that the ...